Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2021 Feb 4

PMID 33536296

Citations 1

Authors

Sara L Revolinski

Christopher D Doern

Affiliations

Soon will be listed here.

Abstract

INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.

Citing Articles

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Bacteremia: STAPH Study.

Alosaimy S, Lagnf A, Morrisette T, Jorgensen S, Trinh T, Zasowski E Open Forum Infect Dis. 2021; 8(7):ofab261.

PMID: 34258313 PMC: 8271135. DOI: 10.1093/ofid/ofab261.

References

Martirosov D, Bidell M, Pai M, Scheetz M, Rosenkranz S, Lodise T . Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study. Diagn Microbiol Infect Dis. 2017; 88(3):259-263. PMC: 5512425. DOI: 10.1016/j.diagmicrobio.2017.03.008. View

Hahn A, Frenck Jr R, Allen-Staat M, Zou Y, Vinks A . Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit. 2015; 37(5):619-25. PMC: 4576725. DOI: 10.1097/FTD.0000000000000190. View

Eum S, Bergsbaken R, Harvey C, Warren J, Rotschafer J . Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus. Antibiotics (Basel). 2016; 5(4). PMC: 5187515. DOI: 10.3390/antibiotics5040034. View

Van Hal S, Lodise T, Paterson D . The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54(6):755-71. DOI: 10.1093/cid/cir935. View

Lodise T, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro B . Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52(9):3315-20. PMC: 2533486. DOI: 10.1128/AAC.00113-08. View

Bae I, Federspiel J, Miro J, Woods C, Park L, Rybak M . Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis. 2009; 200(9):1355-66. PMC: 3600359. DOI: 10.1086/606027. View

Gawronski K, Goff D, Brown J, Khadem T, Bauer K . A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther. 2013; 35(6):772-9. DOI: 10.1016/j.clinthera.2013.05.008. View

Neely M, Youn G, Jones B, Jelliffe R, Drusano G, Rodvold K . Are vancomycin trough concentrations adequate for optimal dosing?. Antimicrob Agents Chemother. 2013; 58(1):309-16. PMC: 3910745. DOI: 10.1128/AAC.01653-13. View

Lodise T, Drusano G, Zasowski E, Dihmess A, Lazariu V, Cosler L . Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?. Clin Infect Dis. 2014; 59(5):666-75. DOI: 10.1093/cid/ciu398. View

10.

Rybak M, Lomaestro B, Rotschafer J, Moellering Jr R, Craig W, Billeter M . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2008; 66(1):82-98. DOI: 10.2146/ajhp080434. View

11.

Finch N, Zasowski E, Murray K, Mynatt R, Zhao J, Yost R . A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrob Agents Chemother. 2017; 61(12). PMC: 5700348. DOI: 10.1128/AAC.01293-17. View

12.

Castaneda X, Garcia-de-la-Maria C, Gasch O, Pericas J, Armero Y, Soy D . AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444163. DOI: 10.1128/AAC.02486-16. View

13.

Heil E, Claeys K, Mynatt R, Hopkins T, Brade K, Watt I . Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm. 2018; 75(24):1986-1995. DOI: 10.2146/ajhp180034. View

14.

Kalil A, Van Schooneveld T, Fey P, Rupp M . Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014; 312(15):1552-64. DOI: 10.1001/jama.2014.6364. View

15.

Moore C, Osaki-Kiyan P, Haque N, Perri M, Donabedian S, Zervos M . Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2011; 54(1):51-8. DOI: 10.1093/cid/cir764. View

16.

Moise-Broder P, Forrest A, Birmingham M, Schentag J . Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43(13):925-42. DOI: 10.2165/00003088-200443130-00005. View

17.

Meng L, Wong T, Huang S, Mui E, Nguyen V, Espinosa G . Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center. Pharmacotherapy. 2019; 39(4):433-442. DOI: 10.1002/phar.2234. View

18.

Rybak M, Lomaestro B, Rotschafer J, Moellering R, Craig W, Billeter M . Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3):325-7. DOI: 10.1086/600877. View

19.

Arshad S, Huang V, Hartman P, Perri M, Moreno D, Zervos M . Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017; 57:27-31. DOI: 10.1016/j.ijid.2017.01.019. View

20.

Rehm S, Boucher H, Levine D, Campion M, Eisenstein B, Vigliani G . Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008; 62(6):1413-21. PMC: 2583068. DOI: 10.1093/jac/dkn372. View